Scalp Psoriasis

Tremfya showed fast and efficacious psoriasis clearance in patients with skin of color in a phase 3b trial, Jannsen announced in a press release.

Healio spoke with Linda Stein Gold, MD, director of dermatology clinical research at Henry Ford Health, about the most difficult-to-treat body areas for psoriasis, treatment options, unmet needs in these cases and more.

Tremfya demonstrated greater treatment persistence than interleukin-17 inhibitors in patients with moderate to severe plaque psoriasis and achieved clinical efficacy in scalp psoriasis, according to data presented here.

The Janssen Pharmaceutical Companies of Johnson & Johnson launched VISIBLE, a phase 3b study with a focus on plaque and scalp psoriasis in people of color, according to a press release.

Scalp psoriasis was improved with a fixed combination of tazarotene and halobetasol propionate lotion, according to an open-label pilot study.

In this video, Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology at the University of Pennsylvania Perelman School of Medicine, discussed phase 2b data on roflumilast foam presented at AAD VMX 2021.

In this video from AAD VMX 2021, Kim A. Papp, MD, discusses a recent study investigating safety and efficacy of once-daily roflumilast foam 0.3% in patients with scalp and body psoriasis.

August is Psoriasis Action Month, a national initiative to encourage understanding and enhance education about this common disease. According to the National Psoriasis Foundation, psoriasis affects more than 8 million Americans and roughly 125 million people worldwide.